LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Home・Akcijų sąrašas・Cogent Biosciences Inc

Cogent Biosciences Inc

Uždarymo kaina

35.68 5.31

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

Max

37.06

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-22M -102M
Pelnas, tenkantis vienai akcijai	-0.5
Darbuotojai	258
EBITDA	-30M -109M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+54.56% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	399M 6B
Ankstesnė atidarymo kaina	30.37
Ankstesnė uždarymo kaina	35.68

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

4.88 / 5.87 Palaikymas ir pasipriešinimas

Cogent Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-15 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026-03-15 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026-03-16 00:00; UTC

Svarbiausios naujienos

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

2026-03-15 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

2026-03-15 23:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

2026-03-15 23:35; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

2026-03-15 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

2026-03-15 22:37; UTC

Rinkos pokalbiai

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

2026-03-15 22:18; UTC

Rinkos pokalbiai

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

2026-03-15 22:00; UTC

Svarbiausios naujienos

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026-03-15 22:00; UTC

Svarbiausios naujienos

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026-03-15 03:00; UTC

Svarbiausios naujienos

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

2026-03-14 15:00; UTC

Svarbiausios naujienos

Iran War Delivers Windfall to America's Oil Country -- WSJ

2026-03-14 02:03; UTC

Uždarbis

This Copper Stock Is Worth Mining for Profits -- Barrons.com

2026-03-14 01:32; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

2026-03-14 00:29; UTC

Įsigijimai, susijungimai, perėmimai

13D Filings -- Barrons.com

2026-03-13 22:27; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

2026-03-13 22:13; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

2026-03-13 22:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

2026-03-13 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

2026-03-13 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-13 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-03-13 20:02; UTC

Rinkos pokalbiai

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

2026-03-13 19:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

2026-03-13 19:35; UTC

Svarbiausios naujienos

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Cogent Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

54.56% į viršų

12 mėnesių prognozė

Vidutinis 52.55 USD 54.56%

Aukščiausias 64 USD

Žemiausias 35 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Cogent Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Cogent Biosciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

4.88 / 5.87Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.